Strategies for Clinical Dose Selection of CDR404: a MAGE-A4/HLA-A2 Antibody-Based T-Cell Engager
Time: 3:30 pm
day: Day 2
Details:
• Using Quantitative Systems Pharmacology (QSP) modeling for dose escalation and FIH study design for CDR404
• We discuss the key preclinical pharmacological data used for generation of a QSP model for CDR404
• Forward-looking perspectives and next generation antibody-based TCEs targeting peptide-HLA on cancer cells
